Banarian Nordic Res (BVNKF) 20.4900 $BVNKF
Bavarian Nordic Announces First Patient Treated in a Phase 1 Study of MVA-BN(r) Brachyury in Advanced Cancer
GlobeNewswire - Thu Jul 24, 12:57AM CDT
Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) announced today that the first patient has been treated in an NCI-sponsored Phase 1 study of MVA-BN Brachyury in patients with advanced cancer.
Bavarian Nordic to Participate in European Midcap Event in Paris
Thomson Reuters ONE - Tue Jun 24, 1:04AM CDT
KVISTGAARD, Denmark - June 24, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that Rolf Sass Sorensen, Vice President Investor Relations & Communications will participate in the European Midcap Event "Spring" in Paris on June 26-27, 2014.
Smallpox - Pipeline Review, H1 2014
M2 - Mon Jun 16, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ndtlnz/smallpox) has announced the addition of the "Smallpox - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Smallpox - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Mentioned: - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Symphogen A/S - Nanotherapeutics, Inc. - CEL-SCI Corporation - GeoVax Labs, Inc. - SIGA Technologies, Inc. - TapImmune Inc. - CJ CheilJedang Corp. - MacroGenics, Inc. - AlphaVax, Inc. - EpiVax, Inc. - Chimerix, Inc. - NanoBio Corporation - Conkwest, Inc. For more information visit http://www.researchandmarkets.com/research/ndtlnz/smallpox
Vaccines 2014-2020: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments (Influenza, Cervical Cancer, Combinations, Hepatitis, Pneumococcal, MMR, Varicella, Poliovirus, HIB, Others)
M2 - Fri Jun 06, 8:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fm23b8/vaccines_2014) has announced the addition of the "Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments (Influenza, Cervical Cancer, Combinations, Hepatitis, Pneumococcal, MMR, Varicella, Poliovirus , HIB, Others)" report to their offering. Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments The global market for human vaccines experienced strong growth through 2013 with the introduction of new vaccines. These new products and other trends are well-covered in Vaccines: The World Market. The Kalorama information report examines the global market for vaccines, covering specifically commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable. Vaccination protects not only individuals, but also entire communities from diseases spread by person-to-person transmission. The high growth rates and successful launch of several recent products have kept interest in the global vaccine market high. This report investigates the changes vaccine manufacturers have undergone in the past year, providing world market analysis, identifying the key players, and outlining critical trends in this fast-changing industry. Included in this report are current market size and forecasts to 2020 for the following vaccines: - Pediatric Vaccines - Pneumococcal - Combinations - Varicella - MMR - Poliovirus - Hepatitis - HIB - Other Pediatric - Adult Vaccines: - Influenza - Cervical Cancer - Hepatitis - Pneumococcal - Travel; DT; Misc. Key Topics Covered: - Executive Summary - Introduction To Vaccines - Pediatric Preventive Vaccines - Adult Preventive Vaccines - Vaccines Market Summary - Issues And Trends - Company Profiles - AlphaVax, Inc. - Bavarian Nordic A/S - Baxter Healthcare - Bharat Biotech - Crucell /Johnson & Johnson - Emergent biosolutions - GlaxoSmithKline - Medimmune - Merck & Co. Inc - Novartis - Pfizer - Sanofi Pasteur For more information visit http://www.researchandmarkets.com/research/fm...cines_2014 About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Bavarian Nordic to Present at Jefferies 2014 Global Healthcare Conference in New York
Thomson Reuters ONE - Wed Jun 04, 11:00AM CDT
KVISTGAARD, Denmark - June 4, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that Ole Larsen, Executive Vice President & CFO will present at the Jefferies 2014 Global Healthcare Conference in New York on Thursday, June 5, 2014 at 9:00 AM EDT.
Bavarian Nordic Announces Appointment of Paul Chaplin, Ph.D. as President & CEO
GlobeNewswire - Wed May 28, 10:12AM CDT
Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) announced today that Paul Chaplin, Ph.D. has been appointed new President and CEO of the Company. He replaces Anders Hedegaard who has served in this position since 2007. Mr. Hedegaard leaves the Company to join GN ReSound A/S as CEO.
Bavarian Nordic A/S Issues New Shares in Connection with Exercise of Warrants
Thomson Reuters ONE - Tue May 27, 5:09AM CDT
KVISTGAARD, Denmark, May 27, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Company's share capital has been increased by nominally DKK 185,020 as a consequence of the exercise of warrants. After registration of the capital increase, Bavarian Nordic A/S' share capital amounts to DKK 261,128,630.
Bavarian Nordic A/S - Notice Convening Ordinary General Meeting
Thomson Reuters ONE - Thu Mar 27, 4:05AM CDT
Pursuant to Article 10 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the ordinary General Meeting to be held on
Bavarian Nordic Announces 2013 Full Year Results
GlobeNewswire - Wed Mar 19, 2:43AM CDT
Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) today published its 2013 annual report. Revenue was DKK 1,213 million / USD 224 million (DKK 1,017 million / USD 188 million in 2012). The Group recorded a profit before tax of DKK 6 million / USD 1 million (DKK 49 million loss / USD 9 million loss in 2012). Revenue and results were in line with the expectations for the year. As planned, the Company delivered 7 million doses of IMVAMUNE(R) to the U.S. in 2013, of which 1.4 million doses relate to the new contract that was entered in April 2013.
Bavarian Nordic to Host Full Year 2013 Results Conference Call
Thomson Reuters ONE - Thu Mar 13, 11:30AM CDT
KVISTGAARD, Denmark - March 13, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) will announce its 2013 full year results on Wednesday, March 19, 2014.
Bavarian Nordic's MVA-BN(R) Vaccine Platform Selected by U.S. Department of Defense for New Vaccine Development
GlobeNewswire - Fri Feb 21, 3:25AM CST
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that its MVA-BN vaccine platform technology has been selected by the Defense Threat Reduction Agency (DTRA), a part of the United States Department of Defense, for the development of a vaccine against two potential biological threats to national security - Burkholderia pseudomallei and Burkholderia mallei.
Bavarian Nordic to Present at the 16th Annual BIO CEO & Investor Conference in New York City
Thomson Reuters ONE - Fri Feb 07, 10:30AM CST
KVISTGAARD, Denmark - February 7, 2014 - Bavarian Nordic (OMX: BAVA, OTC: BVNRY) announced today that James Breitmeyer, MD, PhD and Executive Vice President will present at the 16th Annual BIO CEO & Investor Conference in New York City on Monday, February 10, 2014 at 4:30 p.m. ET.
Ebola and Marburg Infections - Pipeline Review, H2 2013 Report
M2 - Tue Feb 04, 2:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/bv7mx8/ebola_and_marburg) has announced the addition of the "Ebola and Marburg Infections - Pipeline Review, H2 2013" report to their offering. 'Ebola and Marburg Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ebola and Marburg Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ebola and Marburg Infections. Scope - A snapshot of the global therapeutic scenario for Ebola and Marburg Infections. - A review of the Ebola and Marburg Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ebola and Marburg Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Inovio Pharmaceuticals, Inc. Bavarian Nordic A/S Crucell N.V. NanoViricides, Inc. SIGA Technologies, Inc. Functional Genetics, Inc. Okairos AG AlphaVax, Inc. Immunovaccine, Inc. Mapp Biopharmaceutical, Inc. For more information visit http://www.researchandmarkets.com/research/bv...nd_marburg About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Bladder Cancer - Pipeline Review, H2 2013
M2 - Thu Sep 05, 8:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h66gxm/bladder_cancer) has announced the addition of the "Bladder Cancer - Pipeline Review, H2 2013" report to their offering. 'Bladder Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bladder Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bladder Cancer. Scope - A snapshot of the global therapeutic scenario for Bladder Cancer. - A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bladder Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Bladder Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Shionogi & Co., Ltd. Eli Lilly and Company Viralytics Ltd. GlaxoSmithKline plc Seattle Genetics, Inc. Bioniche Life Sciences, Inc. Bavarian Nordic A/S Biotest AG Samyang Corporation Eisai Co., Ltd. MDRNA, Inc. Taiho Pharmaceutical Co., Ltd. Advaxis, Inc. AEterna Zentaris Inc. Alnylam Pharmaceuticals, Inc Oncogenex Pharmaceuticals, Inc. and much more... For more information visit http://www.researchandmarkets.com/research/h6...der_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Prostate Cancer - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tsvj5b/prostate_cancer) has announced the addition of the "Prostate Cancer - Pipeline Review, H2 2013" report to their offering. 'Prostate Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Prostate Cancer. Scope - A snapshot of the global therapeutic scenario for Prostate Cancer. - A review of the Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Prostate Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Boehringer Ingelheim GmbH Celsion Corporation Amgen Inc. Sanofi-Aventis Adherex Technologies Inc. AstraZeneca PLC Eli Lilly and Company Viralytics Ltd. GlaxoSmithKline plc Bioniche Life Sciences, Inc. Genentech, Inc. Inovio Biomedical Corporation Bavarian Nordic A/S Isis Pharmaceuticals, Inc. Biotest AG GenVec, Inc. Merck & Co., Inc. AbGenomics International, Inc. Emergent BioSolutions Inc. Oxford BioMedica plc and many more... For more information visit http://www.researchandmarkets.com/research/ts...ate_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Bavarian Nordic Reports Financial Results for the First Half of 2013
GlobeNewswire - Thu Aug 22, 1:51AM CDT
Bavarian Nordic A/S (OMX:BAVA) today publishes its results for the first half of 2013. Revenue for the period was DKK 556 million (2012: DKK 445 million) and the result before tax was a loss of DKK 43 million (2012: DKK 13 million loss). The Infectious Disease division remains profitable with an EBIT after internal allocations of DKK 131 million in the period (2012: DKK 116 million). As of June 30, 2013 the cash preparedness was DKK 695 million, including unutilized credit lines of DKK 120 million. The company has research and delivery contracts with the U.S. Government of which payments of up to USD 384 million (approximately DKK 2.1 billion) remain as of June 30, 2013. The company maintains its 2013 full-year expectations with revenues in the level of DKK 1,100 million and a break-even result before tax. The cash preparedness at year-end is expected to be roughly DKK 600 million.
Bavarian Nordic Announces First Patient Treated in a Phase 1 Study of MVA-BN(r) Brachyury in Advanced Cancer
GlobeNewswire - Thu Jul 24, 12:57AM CDT
Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) announced today that the first patient has been treated in an NCI-sponsored Phase 1 study of MVA-BN Brachyury in patients with advanced cancer.
Bavarian Nordic to Participate in European Midcap Event in Paris
Thomson Reuters ONE - Tue Jun 24, 1:04AM CDT
KVISTGAARD, Denmark - June 24, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that Rolf Sass Sorensen, Vice President Investor Relations & Communications will participate in the European Midcap Event "Spring" in Paris on June 26-27, 2014.
Smallpox - Pipeline Review, H1 2014
M2 - Mon Jun 16, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ndtlnz/smallpox) has announced the addition of the "Smallpox - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Smallpox - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Mentioned: - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Symphogen A/S - Nanotherapeutics, Inc. - CEL-SCI Corporation - GeoVax Labs, Inc. - SIGA Technologies, Inc. - TapImmune Inc. - CJ CheilJedang Corp. - MacroGenics, Inc. - AlphaVax, Inc. - EpiVax, Inc. - Chimerix, Inc. - NanoBio Corporation - Conkwest, Inc. For more information visit http://www.researchandmarkets.com/research/ndtlnz/smallpox
Vaccines 2014-2020: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments (Influenza, Cervical Cancer, Combinations, Hepatitis, Pneumococcal, MMR, Varicella, Poliovirus, HIB, Others)
M2 - Fri Jun 06, 8:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fm23b8/vaccines_2014) has announced the addition of the "Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments (Influenza, Cervical Cancer, Combinations, Hepatitis, Pneumococcal, MMR, Varicella, Poliovirus , HIB, Others)" report to their offering. Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments The global market for human vaccines experienced strong growth through 2013 with the introduction of new vaccines. These new products and other trends are well-covered in Vaccines: The World Market. The Kalorama information report examines the global market for vaccines, covering specifically commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable. Vaccination protects not only individuals, but also entire communities from diseases spread by person-to-person transmission. The high growth rates and successful launch of several recent products have kept interest in the global vaccine market high. This report investigates the changes vaccine manufacturers have undergone in the past year, providing world market analysis, identifying the key players, and outlining critical trends in this fast-changing industry. Included in this report are current market size and forecasts to 2020 for the following vaccines: - Pediatric Vaccines - Pneumococcal - Combinations - Varicella - MMR - Poliovirus - Hepatitis - HIB - Other Pediatric - Adult Vaccines: - Influenza - Cervical Cancer - Hepatitis - Pneumococcal - Travel; DT; Misc. Key Topics Covered: - Executive Summary - Introduction To Vaccines - Pediatric Preventive Vaccines - Adult Preventive Vaccines - Vaccines Market Summary - Issues And Trends - Company Profiles - AlphaVax, Inc. - Bavarian Nordic A/S - Baxter Healthcare - Bharat Biotech - Crucell /Johnson & Johnson - Emergent biosolutions - GlaxoSmithKline - Medimmune - Merck & Co. Inc - Novartis - Pfizer - Sanofi Pasteur For more information visit http://www.researchandmarkets.com/research/fm...cines_2014 About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Bavarian Nordic to Present at Jefferies 2014 Global Healthcare Conference in New York
Thomson Reuters ONE - Wed Jun 04, 11:00AM CDT
KVISTGAARD, Denmark - June 4, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that Ole Larsen, Executive Vice President & CFO will present at the Jefferies 2014 Global Healthcare Conference in New York on Thursday, June 5, 2014 at 9:00 AM EDT.
Bavarian Nordic Announces Appointment of Paul Chaplin, Ph.D. as President & CEO
GlobeNewswire - Wed May 28, 10:12AM CDT
Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) announced today that Paul Chaplin, Ph.D. has been appointed new President and CEO of the Company. He replaces Anders Hedegaard who has served in this position since 2007. Mr. Hedegaard leaves the Company to join GN ReSound A/S as CEO.
Bavarian Nordic A/S Issues New Shares in Connection with Exercise of Warrants
Thomson Reuters ONE - Tue May 27, 5:09AM CDT
KVISTGAARD, Denmark, May 27, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Company's share capital has been increased by nominally DKK 185,020 as a consequence of the exercise of warrants. After registration of the capital increase, Bavarian Nordic A/S' share capital amounts to DKK 261,128,630.
Bavarian Nordic A/S - Notice Convening Ordinary General Meeting
Thomson Reuters ONE - Thu Mar 27, 4:05AM CDT
Pursuant to Article 10 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the ordinary General Meeting to be held on
Bavarian Nordic Announces 2013 Full Year Results
GlobeNewswire - Wed Mar 19, 2:43AM CDT
Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) today published its 2013 annual report. Revenue was DKK 1,213 million / USD 224 million (DKK 1,017 million / USD 188 million in 2012). The Group recorded a profit before tax of DKK 6 million / USD 1 million (DKK 49 million loss / USD 9 million loss in 2012). Revenue and results were in line with the expectations for the year. As planned, the Company delivered 7 million doses of IMVAMUNE(R) to the U.S. in 2013, of which 1.4 million doses relate to the new contract that was entered in April 2013.
Bavarian Nordic to Host Full Year 2013 Results Conference Call
Thomson Reuters ONE - Thu Mar 13, 11:30AM CDT
KVISTGAARD, Denmark - March 13, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) will announce its 2013 full year results on Wednesday, March 19, 2014.
Bavarian Nordic's MVA-BN(R) Vaccine Platform Selected by U.S. Department of Defense for New Vaccine Development
GlobeNewswire - Fri Feb 21, 3:25AM CST
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that its MVA-BN vaccine platform technology has been selected by the Defense Threat Reduction Agency (DTRA), a part of the United States Department of Defense, for the development of a vaccine against two potential biological threats to national security - Burkholderia pseudomallei and Burkholderia mallei.
Bavarian Nordic to Present at the 16th Annual BIO CEO & Investor Conference in New York City
Thomson Reuters ONE - Fri Feb 07, 10:30AM CST
KVISTGAARD, Denmark - February 7, 2014 - Bavarian Nordic (OMX: BAVA, OTC: BVNRY) announced today that James Breitmeyer, MD, PhD and Executive Vice President will present at the 16th Annual BIO CEO & Investor Conference in New York City on Monday, February 10, 2014 at 4:30 p.m. ET.
Ebola and Marburg Infections - Pipeline Review, H2 2013 Report
M2 - Tue Feb 04, 2:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/bv7mx8/ebola_and_marburg) has announced the addition of the "Ebola and Marburg Infections - Pipeline Review, H2 2013" report to their offering. 'Ebola and Marburg Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ebola and Marburg Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ebola and Marburg Infections. Scope - A snapshot of the global therapeutic scenario for Ebola and Marburg Infections. - A review of the Ebola and Marburg Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ebola and Marburg Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Inovio Pharmaceuticals, Inc. Bavarian Nordic A/S Crucell N.V. NanoViricides, Inc. SIGA Technologies, Inc. Functional Genetics, Inc. Okairos AG AlphaVax, Inc. Immunovaccine, Inc. Mapp Biopharmaceutical, Inc. For more information visit http://www.researchandmarkets.com/research/bv...nd_marburg About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Bladder Cancer - Pipeline Review, H2 2013
M2 - Thu Sep 05, 8:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h66gxm/bladder_cancer) has announced the addition of the "Bladder Cancer - Pipeline Review, H2 2013" report to their offering. 'Bladder Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bladder Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bladder Cancer. Scope - A snapshot of the global therapeutic scenario for Bladder Cancer. - A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bladder Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Bladder Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Shionogi & Co., Ltd. Eli Lilly and Company Viralytics Ltd. GlaxoSmithKline plc Seattle Genetics, Inc. Bioniche Life Sciences, Inc. Bavarian Nordic A/S Biotest AG Samyang Corporation Eisai Co., Ltd. MDRNA, Inc. Taiho Pharmaceutical Co., Ltd. Advaxis, Inc. AEterna Zentaris Inc. Alnylam Pharmaceuticals, Inc Oncogenex Pharmaceuticals, Inc. and much more... For more information visit http://www.researchandmarkets.com/research/h6...der_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Prostate Cancer - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tsvj5b/prostate_cancer) has announced the addition of the "Prostate Cancer - Pipeline Review, H2 2013" report to their offering. 'Prostate Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Prostate Cancer. Scope - A snapshot of the global therapeutic scenario for Prostate Cancer. - A review of the Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Prostate Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Boehringer Ingelheim GmbH Celsion Corporation Amgen Inc. Sanofi-Aventis Adherex Technologies Inc. AstraZeneca PLC Eli Lilly and Company Viralytics Ltd. GlaxoSmithKline plc Bioniche Life Sciences, Inc. Genentech, Inc. Inovio Biomedical Corporation Bavarian Nordic A/S Isis Pharmaceuticals, Inc. Biotest AG GenVec, Inc. Merck & Co., Inc. AbGenomics International, Inc. Emergent BioSolutions Inc. Oxford BioMedica plc and many more... For more information visit http://www.researchandmarkets.com/research/ts...ate_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Bavarian Nordic Reports Financial Results for the First Half of 2013
GlobeNewswire - Thu Aug 22, 1:51AM CDT
Bavarian Nordic A/S (OMX:BAVA) today publishes its results for the first half of 2013. Revenue for the period was DKK 556 million (2012: DKK 445 million) and the result before tax was a loss of DKK 43 million (2012: DKK 13 million loss). The Infectious Disease division remains profitable with an EBIT after internal allocations of DKK 131 million in the period (2012: DKK 116 million). As of June 30, 2013 the cash preparedness was DKK 695 million, including unutilized credit lines of DKK 120 million. The company has research and delivery contracts with the U.S. Government of which payments of up to USD 384 million (approximately DKK 2.1 billion) remain as of June 30, 2013. The company maintains its 2013 full-year expectations with revenues in the level of DKK 1,100 million and a break-even result before tax. The cash preparedness at year-end is expected to be roughly DKK 600 million.
